Results 31 to 40 of about 6,010 (179)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol

JACC: Case Reports, 2020
We describe a case of stress-induced cardiomyopathy following epoprostenol withdrawal. A patient with pulmonary arterial hypertension presented with a malfunctioning Hickman catheter. Inappropriate withdrawal of epoprostenol resulted in shock. Evaluation
William J. Gionfriddo, MD, Hanna N. Ahmed, MD, Harrison W. Farber, MD   +2 more
doaj   +1 more source

Epoprostenol sodium for treatment of pulmonary arterial hypertension [PDF]

, 2015
The release of endogenous prostacyclin (PGI2) is depressed in patients with pulmonary arterial hypertension (PAH). PGI2 replacement therapy by epoprostenol infusion is one of the best treatments available for PAH.
Nakamura, Kazufumi, Saito, Yukihiro, Sarashina, Toshihiro, Matsubara, Hiromi, Miura, Aya, Ejiri, Kentaro, Ito, Hiroshi, Ogawa, Aiko, Akagi, Satoshi   +8 more
core   +2 more sources

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Respiratory Research, 2023
Background Epoprostenol AS (Veletri®), a thermostable epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri®,
Julia Degering, Benjamin Egenlauf, Satenik Harutyunova, Nicola Benjamin, Amina Salkić, Panagiota Xanthouli, Christina A. Eichstaedt, Rebekka Seeger, Olivier Sitbon, Ekkehard Grünig   +9 more
doaj   +1 more source

Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry. [PDF]

Pulm Circ
ABSTRACT Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent.
Smukowska-Gorynia A, Iwańczyk S, Ciurzyński M, Waligóra M, Kurzyna M, Pruszczyk P, Kopeć G, Mizia-Stec K, Skoczylas I, Chrzanowski Ł, Błaszczak P, Ptaszyńska K, Grześk G, Malinowska E, Peregud-Pogorzelska M, Tomaszewski M, Mroczek E, Jaguszewski M, Lewicka E, Widejko K, Pawlak A, Jacheć W, Gąsior Z, Betkier-Lipińska K, Winowska-Józwa J, Banaszkiewicz M, Mularek-Kubzdela T.   +26 more
europepmc   +2 more sources

Epoprostenol Therapy for Pulmonary Arterial Hypertension [PDF]

, 2015
Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death.
Nakamura, Kazufumi, Matsubara, Hiromi, Sarashina, Toshihiro, Ejiri, Kentaro, Ito, Hiroshi, Ogawa, Aiko, Akagi, Satoshi   +6 more
core   +1 more source

Improved ventricular function during inhalation of PGI(2) aerosol partly relies on enhanced myocardial contractility [PDF]

, 2005
Inhaled prostacyclin (PGI(2)) aerosol induces selective pulmonary vasodilation. Further, it improves right ventricular ( RV) function, which may largely rely on pulmonary vasodilation, but also on enhanced myocardial contractility.
Thein, E., Kisch-Wedel, H., Kemming, G., Bruhn, S., Meisner, F., Meisner, D., Kreyling, W., Zwissler, B., Flondor, M., Kreyling, W.G., Zwissler, Bernhard, Hofstetter, C., Kemming, Gregor   +12 more
core   +1 more source

Case report: Transected Hickman catheter and its thrombotic occlusion in a patient with idiopathic pulmonary arterial hypertension—can a catheter replacement be avoided?

Frontiers in Cardiovascular Medicine, 2023
A 25-year-old female with idiopathic pulmonary arterial hypertension (PAH), who had a Hickman catheter implanted for continuous intravenous epoprostenol infusion, was admitted to the clinic after inadvertently cutting the catheter with nail scissors ...
Grzegorz Sławiński, Grzegorz Sławiński, Piotr Zieleniewicz, Anna Faran, Alicja Dąbrowska-Kugacka, Marcin Kurzyna, Maciej Kempa, Ludmiła Daniłowicz-Szymanowicz, Ewa Lewicka   +8 more
doaj   +1 more source

Temperature variations around medication cassette and carry bag in routine use of epoprostenol administration in healthy volunteers. [PDF]

PLoS ONE, 2012
BACKGROUND: According to several treatment guidelines, epoprostenol is an important treatment option for pulmonary arterial hypertension. However, the pharmacokinetic characteristics and poor stability of epoprostenol at room temperature make its ...
Yuichi Tamura, Yasuo Nakajima, Yasushi Ozeki, Tomohiko Ono, Makoto Takei, Tsunehisa Yamamoto, Keiichi Fukuda   +6 more
doaj   +1 more source

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension

Pulmonary Circulation, 2021
While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment.
Kellie Morland, Amresh Raina, Abigail Nails, Peter Classi, Martine Etschmaier, Robert P. Frantz   +5 more
doaj   +1 more source

No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial

BMC Pulmonary Medicine, 2010
Background Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically.
Boonstra Anco B, Kamp Otto, IJzerman Richard G, Kooter Albertus J, Smulders Yvo M   +4 more
doaj   +1 more source